Myeloid-biased HSC require Semaphorin 4A from the bone marrow niche for self-renewal under stress and life-long persistence

Dorsa Toghani^{1,13}, Sharon Zeng^{1,13}, Elmir Mahammadov^{2,14}, Edie I. Crosse^{1,14}, Negar Seyedhassantehrani³, Christian Burns³, David Gravano³, Stefan Radtke¹, Hans-Peter Kiem¹, Sonia Rodriguez⁴, Nadia Carlesso⁴, Amogh Pradeep¹, Nicola K. Wilson⁵, Sarah J. Kinston⁵, Berthold Göttgens⁵, Claus Nerlov⁶, Eric Pietras⁷, Marion Mesnieres⁸, Christa Maes⁸, Atsushi Kumanogoh⁹, Thomas Worzfeld^{10,11}, Peter Kharchenko¹², David T. Scadden¹², Antonio Scialdone², Joel A Spencer³, and Lev Silberstein^{1*}

¹Fred Hutchinson Cancer Research Center, Seattle, USA, ²Helmholtz Zentrum Muenchen, Munich, Germany, ³University of California Merced, USA, ⁴Beckman Research Institute, City of Hope, USA, ⁵ Department of Haematology, Jeffrey Cheah Biomedical Centre, Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge, UK, ⁶University of Oxford, UK, ⁷University of Colorado, USA, ⁸KU Leuven, Belgium, ⁹University of Osaka, Japan, ¹⁰University of Marburg, Germany, ¹¹Max-Planck-Institute for Heart and Lung Research, Germany, ¹²Harvard University, Boston, USA

¹³DT and SZ contributed equally

¹⁴EM and EIC contributed equally

*Corresponding author, email lsilbers@fredhutch.org

SUMMARY

Tissue stem cells are hierarchically organized. Those that are most primitive serve as key drivers of regenerative response but the signals that selectively preserve their functional integrity are largely unknown. Here, we identify a secreted factor, Semaphorin 4A (Sema4A), as a specific regulator of myeloid-biased hematopoietic stem cells (myHSC), which are positioned at the top of the HSC hierarchy. Lack of Sema4A leads to exaggerated myHSC (but not downstream “balanced” HSC) proliferation after acute inflammatory stress, indicating that Sema4A enforces myHSC quiescence. Strikingly, aged Sema4A knock-out myHSC expand but almost completely lose reconstitution capacity. The effect of Sema4A is non cell-autonomous, since upon transplantation into Sema4A-deficient environment, wild-type myHSC excessively proliferate but fail to engraft long-term. Sema4A constrains inflammatory signaling in myHSC and acts via a surface receptor Plexin-D1. Our data support a model whereby the most primitive tissue stem cells critically rely on a dedicated signal from the niche for self-renewal and life-long persistence.

Hematopoietic Stem Cells, Inflammation, Aging, Niche

INTRODUCTION

In multiple tissues, stem cells are hierarchically organized and contain distinct, functionally specialized subsets. For example, in the brain (Sachewsky et al., 2019), skeletal muscle (Scaramozza et al., 2019), cornea (Altshuler et al., 2021; Farrelly et al., 2021) and skin (Hsu et al., 2011; Rompolas et al., 2013), the most primitive stem cells (which are also largely quiescent) become activated by injury or stress, whereas their “downstream”, more differentiated counterparts are more proliferative and mainly engaged in on-going tissue repair. Although this two-tiered organization of the stem cell compartment is essential for life-long

tissue maintenance, the mechanisms that ensure functional preservation and persistence of individual stem cell subsets within a tissue stem cell hierarchy remain largely unknown.

In the bone marrow, the stem cell hierarchy is exemplified by the myeloid-biased and “balanced” (HSC) subsets, in which the former is considered the most primitive (Challen et al., 2010; Morita et al., 2010; Sanjuan-Pla et al., 2013). Compared to balanced HSC (balHSC), myeloid-biased HSC (myHSC) are inherently skewed towards myeloid differentiation, endowed with a higher self-renewal potential and possess a superior ability to enter cell cycle in response to inflammatory stress (Mann et al., 2018; Matatall et al., 2014; Mitroulis et al., 2018). Although these properties are beneficial for powerful and timely host defense response, they likely account for myHSC expansion during inflammation and aging, which is associated with profound and irreversible functional loss (Beerman et al., 2010; Esplin et al., 2011; Grover et al., 2016; Pang et al., 2011). Thus, despite being positioned at the top of the HSC hierarchy, myHSC appear most vulnerable to stress-induced damage.

In the current study, we identify a membrane-bound and secreted protein Semaphorin 4A (Sema4A) as a myHSC-protective factor. We show that under stress conditions, such as aging and transplantation, the absence of Sema4A results in excessive expansion and functional attrition of myHSC. Surprisingly, balHSC are only minimally affected, suggesting that the effect of Sema4A is myHSC-specific. We further demonstrate that Sema4A from the bone marrow niche is essential for myHSC self-renewal and identify Plexin-D1 as a functional receptor. Our results reveal that by selectively preserving a functional myHSC pool, Sema4A plays a key role in long-term maintenance of the HSC hierarchy.

RESULTS

Sema4A regulates quiescence of mouse and human hematopoietic stem/progenitor cells

We have previously established proximity-based analysis as a platform for niche factor discovery (Silberstein et al., 2016). We compared single cell RNA-Seq signatures of osteolineage cells (OLC) that were located in close proximity to a single transplanted HSC (proximal OLC) and further away (distal OLC), and functionally validated several secreted factors with a higher expression in proximal OLC (Angiogenin, IL18, Embigin, VEGF-C) as non cell-autonomous regulators of hematopoietic stem cell/progenitor quiescence (Fang et al., 2020; Goncalves et al., 2016; Silberstein *et al.*, 2016). Because Sema4A displayed a similar expression difference by being significantly more abundant in proximal OLC, as shown in Fig. 1A, we hypothesized that it could also act as a niche-derived HSC quiescence regulator.

Semaphorins are a large family of membrane-bound and/or secreted proteins which mediate cell-cell communications in neural development, angiogenesis, immune response and cancer (Fard and Tamagnone, 2021; Kolodkin et al., 1993). In keeping with our hypothesis for a possible non cell-autonomous regulatory role of Sema4A in hematopoiesis, we found that Sema4A transcripts were detectable in niche cell subsets, such as CD31⁺ endothelial cells and niche factor-enriched VCAM1^{high}Embigin⁺ OLC fraction, as also supported by the published data (Baccin et al., 2020) (Fig. S1A and S1B). Of note, expression of Sema4A in CD45⁺Ter119⁺ ALCAM⁺ bone-lining cells (Valletta et al., 2020) was significantly increased in aged mice (Fig. S1C). In human bone marrow, Sema4A mRNA was also present in bone-lining and endothelial cells, as demonstrated by single-molecule fluorescent in situ hybridization (Fig. S1D).

In order to gain initial functional insights, we tested the effect of Sema4A on proliferation of mouse and human hematopoietic stem/progenitor cells *in vitro*. Consistent with our hypothesis, addition of recombinant Sema4A-Fc protein resulted in fewer lin⁻c-Kit⁺Sca-1⁺ (LKS) cells after 24 hours of liquid culture and suppression of hematopoietic colony formation in a dose-dependent manner (Fig. 1B and S1E). Similarly, human recombinant Sema4A-Fc inhibited *in vitro* proliferation of human bone marrow CD34⁺ cells from several donors, as measured by the Carboxyfluorescein succinimidyl ester (CFSE) dilution assay (Takizawa et al., 2011) (Fig. 1C and S1F). Collectively, these data indicate that Sema4A non cell-autonomously restricts HSPC proliferation, and that this property is conserved between mice and humans.

Next, we examined the role of Sema4A in steady-state hematopoiesis using a germline knock-out model. Sema4A knock-out (Sema4AKO) mice are viable and have a normal life span (Kumanogoh et al., 2005). However, baseline analysis of young Sema4AKO animals revealed subtle but reproducible anemia and thrombocytosis (Fig. S1G). Moreover, in the bone marrow, while the number and frequency of long-term HSC (LT-HSC, defined as LKS CD48⁻CD34⁻Fli2⁻CD150⁺) was similar between the genotypes, the differentiation was skewed towards the myeloid lineage, as evidenced by increased frequency of myeloid-committed progenitors MPP2 and mature myeloid cells (Fig. 1D, see Fig. S1H for gating strategy). Importantly, young Sema4AKO HSC displayed more active cycling, as assessed by Ki-67/DAPI staining and EdU incorporation (Fig. 1E, S1I and S1J). Single-cell RNA-Seq of HSPC from young WT and Sema4AKO mice, while showing no difference in cluster distribution (Fig. S1K), revealed positive enrichment for the terms “Kegg ribosome” and “Electron transport chain oxphos system in mitochondria” in Sema4AKO cells within the HSC cluster, consistent with disruption of quiescence (Fig. 1F, 1G, S1L, and Suppl. File). Collectively, these results indicate that loss of Sema4A leads to increased HSC proliferation, metabolic activation and myeloid-biased differentiation.

Sema4A/PlxnD1 signaling constrains the response of myeloid-biased HSC to proliferative stress

Given recent evidence suggesting that lineage-restricted HSC subsets are differentially regulated by niche-derived signals, we hypothesized that myeloid bias in the Sema4AKO model is due to the lack of quiescence-inducing effect of Sema4A specifically on myHSC. While baseline analysis demonstrated no appreciable difference in cell cycle status between Sema4AKO myHSC (LKS CD48⁻CD34⁻Fli2⁻CD150^{high}) and balHSC (LKS CD48⁻CD34⁻Fli2⁻CD150^{low}) (Beerman *et al.*, 2010) [data not shown], exposure to acute inflammatory stress revealed important HSC subset-specific differences.

In particular, twenty-four hours after injection with polyinosinic:polycytidilic acid (Poly (I:C)) (Walter *et al.*, 2015)(Fig 2A), we found a significant increase in the percentage of Sema4AKO myHSC in G2M phase of cell cycle (Fig.2B and S2B) while no cell cycle difference was observed in balHSC subset (Fig. 2C and S2C, see Fig. S2A for gating strategy under inflammatory conditions) (Hirche *et al.*, 2017). Of note, myHSC and balHSC cycling was comparable in PBS-injected WT/Sema4AKO animals (Fig S2D and S2E) suggesting that the above changes in Sema4AKO myHSC were due to exaggerated response to inflammatory stress. Indeed, subsequent RNA-Seq analysis of myHSC and balHSC from Poly (I:C)-injected animals revealed enrichment for the terms “IL6-Jak Stat3 signaling” and “Interferon alpha response” which was unique to Sema4AKO myHSC dataset (Fig. 2D, 2E, S2F, Suppl. File). Thus, our results reveal that the absence of Sema4A promotes myHSC cell cycle entry and lead to enhanced myHSC sensitivity to inflammatory signaling.

Next, we asked if *Sema4A* deletion differentially impacts long-term reconstitution capacity of the two HSC subsets. To this end, we isolated myHSC and balHSC from WT and *Sema4AKO* (CD45.2) donors and transplanted equal number of cells from each subset into lethally irradiated WT (CD45.1) recipients (Fig. 2F). As shown in Fig. 2G, *Sema4AKO* myHSC displayed a significantly higher level of post-transplant reconstitution as compared to WT myHSC controls, with the difference increasing over time (see Fig. S2G for gating strategy used in chimerism analysis). In contrast, this trend was considerably weaker in the recipients of WT/*Sema4AKO* balHSC and no longer detectable 24 weeks post-transplant (Fig. 2H). In addition, *Sema4AKO* myHSC (but not balHSC) graft displayed excessive lymphoid skewing (Fig. S2H and S2I). These data provide further support for the myHSC-specific action of *Sema4A*, as evidenced by enhanced output and impaired differentiation of transplanted *Sema4AKO* myHSC.

In order to establish a cellular mechanism for this effect, we sought to identify a functional receptor for *Sema4A* on myHSC. Analysis of published HSC gene expression datasets (Cabezas-Wallscheid et al., 2017; Cabezas-Wallscheid et al., 2014) revealed that amongst known receptors for *Sema4A*, Plexin-B2 (*PlxnB2*) and Plexin-D1 (*PlxnD1*) had the highest expression level in HSC (Fig. 2I). However, *PlxnB2* has been described as a receptor for Angiogenin (Yu et al., 2017) which has no effect on myeloid differentiation (Goncalves *et al.*, 2016). We therefore considered *PlxnD1* the most likely candidate. Interestingly, the ability of *Sema4A*/*PlxnD1* signaling to constrain stress-induced proliferation (as it would be for myHSC) has been already shown for the endothelial cells (Toyofuku et al., 2007). Furthermore, our analysis of *PlxnD1*-GFP reporter mice (Gong et al., 2003) revealed a significantly higher level of *PlxnD1* expression in myHSC as compared to balHSC (Fig. 2J), which was consistent with a predominant functional effect of *Sema4A*. Of note, a fraction of CD34⁺CD90⁺ human HSC also expressed *PlxnD1* (Fig. S2J).

Global deletion of PlxnD1 in mice is embryonic lethal due to structural cardiac and vascular defects (Serini et al., 2003), thus precluding functional analysis of adult HSC from these animals. We therefore conditionally deleted PlxnD1 by crossing PlxnD1 “floxed” (Zhang et al., 2009) mice with the Mx1-Cre strain (Kuhn et al., 1995). We confirmed a complete excision of PlxnD1 by PCR and Q-PCR analysis of sorted LKS cells after Poly (I:C) induction (Fig. S2K and S2L). Baseline analysis of PlxnD1^{fl/fl} Mx1-Cre(+) and PlxnD1^{fl/fl} Mx1-Cre(-) mice revealed no significant differences in blood counts, HSC cell cycle and HSPC and mature cell frequency, except for a slight increase in MPP2 and lin⁻Sca-1^c-Kit⁺ myeloid progenitors, suggesting myeloid bias (Fig. S2M and S2N, Suppl. Table 1). However, competitive transplantation of myHSC and balHSC from PlxnD1^{fl/fl} Mx1-Cre(+) and PlxnD1^{fl/fl} Mx1-Cre(-) mice revealed significantly higher reconstitution by PlxnD1-deficient myHSC while their balHSC counterparts engrafted normally, thus recapitulating the phenotype of transplanted myHSC and balHSC from Sema4AKO mice (Fig. 2K-L and S2O-Q). In sum, our results are consistent with a previously unrecognized role of PlxnD1 as a functional receptor for Sema4A on myHSC.

Sema4A prevents excessive myHSC expansion and functional loss with age

Our observation that Sema4A loss enhances myHSC responsiveness to proliferative challenges, such as acute inflammation and transplantation, prompted us to investigate whether this will lead to impaired myHSC function upon chronic inflammatory stimulation, as occurs during aging (Kovtonyuk et al., 2016). Analysis of peripheral blood in aged Sema4AKO mice revealed progressive anemia, thrombocytosis and neutrophilia (Fig. 3A). In order to rule out systemic inflammation as a cause of the above abnormalities, we examined the plasma levels of 36 proinflammatory cytokines in aged WT and Sema4AKO mice (including thrombopoietin and G-CSF) but detected no significant differences (Suppl. Table 2).

Immunophenotypic analysis of the bone marrow in aged Sema4AKO mice demonstrated a higher number of primitive hematopoietic cells and marked myeloid expansion, as evidenced by increased frequency and absolute number of myeloid progenitors and mature myeloid cells (Fig. 3B and S3A). Critically, we observed a marked (~2.5-fold) increase in the absolute number of myHSC while the number of balHSC was comparable with that of aged-matched WT controls (Fig. 3C and S3B).

The amplified aged Sema4AKO myHSC population may represent either expanded *bona fide* myHSC or a more differentiated progeny which retained immunophenotypic features of myHSC but lost long-term regenerative potential following expansion (Bernitz et al., 2016). To distinguish between these two possibilities, we competitively transplanted equal numbers of myHSC from aged Sema4AKO and WT animals into lethally irradiated WT recipients (Fig. 3D).

Strikingly, aged Sema4AKO myHSC, while still displaying myeloid bias, generated a markedly lower level of donor chimerism in peripheral blood (range 0-1.43% vs 9.93-77.5% in aged WT myHSC controls) (Fig. 3E and S3C) and failed to produce a detectable long-term graft in the bone marrow (Fig. S3E). In contrast, balHSC from both WT and Sema4AKO mice gave rise to comparable levels of peripheral blood and bone marrow donor chimerism (Fig. 3F and S3D). These data demonstrate that during aging, Sema4A absence leads to profound functional attrition of phenotypic myHSC but is inconsequential for balHSC.

Aiming to understand the molecular events which are responsible for the myHSC-specific effect of Sema4A, we performed single cell RNA-Seq analysis of myHSC and balHSC from aged WT and Sema4AKO mice using the Smart-Seq2 protocol (Picelli et al., 2014). We sorted 192 cells per group (768 total), of which 642 were selected for analysis following quality control (see Methods). As expected, WT myHSC had a higher expression of *Slamf1*, self-renewal/low-

output-associated genes (*CD74*, *Ly6a*, *vWF*, *Procr*) and lower expression of cell cycle-related genes (*Cdk6* and *Mki67*) as compared to WT balHSC (Fig. S3F) (Becker-Herman et al., 2021; Kent et al., 2009; Kent et al., 2008; Laurenti et al., 2015; Morcos et al., 2017; Rodriguez-Fraticelli et al., 2020).

A transcriptome-wide analysis revealed that within the myHSC fraction, WT and Sema4AKO cells formed distinct, minimally overlapping clusters (Fig. 3G) while balHSC of both genotypes merged together, indicating that the absence of Sema4A induces transcriptional changes predominantly in myHSC (Fig. 3H). We quantified this HSC subset-specific difference by detecting a greater correlation-based distance between WT/ Sema4AKO myHSC compared to WT/ Sema4AKO balHSC (Fig. 3I); Wilcoxon Rank-Sum test, p-value 3.1e-85, see Methods for further details).

Next, we examined the transcriptional features of the above aged HSC subsets in more detail. Consistent with the results of the clustering analysis, the number of genes which were differentially expressed in aged Sema4AKO vs WT myHSC was much greater (431) compared to aged Sema4AKO vs WT balHSC (30). In the aged Sema4AKO myHSC signature, we noted markedly reduced expression of genes that normally constrain HSC pool and promote HSC self-renewal (*CD74*, *vWF*, *Ly6a*, *Mllt3*) (Becker-Herman et al., 2021; Calvanese et al., 2019; Kent et al., 2009; Kent et al., 2008), consistent with their excessive expansion and loss of stemness (Fig. S3G). Moreover, GSEA demonstrated a significant enrichment for the terms “p53 pathways” (top genes: *Jun*, *Fos*, *Sesn1*) and “TNF-alpha/NFkB signaling” (top genes: *Fosb*, *Egr1*, *Jun*) and as well as a recently defined “core aging HSC signature” (Svendsen et al, 2021) (Fig. 3J, 3K, S3H, Suppl. File).

While “TNF-alpha/NFkB signaling” was also enriched in aged Sema4AKO balHSC (Fig. S3I), no enrichment for “p53 pathway” was observed, and enrichment for the “core aging HSC signature” was much weaker (FDR=0.09, P=0.047 for balHSC vs FDR=0.002, P=0.001 for myHSC, (Fig.S3H and data not shown). These findings suggest that in the absence of Sema4A, aged myHSC sustain a greater degree of stress- and inflammation-induced damage (Walter *et al.*, 2015). Consistent with this notion, *in silico* cell cycle analysis (Scialdone et al., 2015) revealed reduced cycling in aged Sema4AKO myHSC but not in balHSC (Fig. 3L). While loss of proliferative capacity in myHSC occurs during normal aging (Montecino-Rodriguez et al., 2019), it was more prominent in aged Sema4AKO myHSC. In conjunction with other phenotypic (expansion and functional loss) and molecular (aging HSC signature) features of normal aging which were exaggerated in aged Sema4AKO myHSC, this suggests that the absence of Sema4A leads to premature myHSC aging.

Given that amplification of aged Sema4AKO phenotypic myHSC was accompanied by a marked expansion of downstream myeloid progeny, we wondered if accelerated differentiation was another factor which would explain their functional loss. We addressed this question using diffusion pseudotime (DPT) analysis (Haghverdi et al., 2016), which can quantify the differentiation state of each cell going from naive (corresponding to HSC) to more mature (multipotent progenitors, MPP). To this end, we first generated 10x Genomics single cell RNA-Seq profiles of $\text{lin}^- \text{c-Kit}^+$ HSPC from 74-weeks old WT animals, i.e. age-matched with WT/Sema4AKO animals for the Smart-Seq2 single-cell RNA-Seq experiment described above. In this 10x dataset, by mapping expression of previously described markers (Nestorowa et al., 2016) we identified the clusters that correspond to HSC (Cluster 2; *Ly6a*, *Procr*, *Hlf*) and MPP (Cluster 0; *Cd34*, *Cebpa*, *Ctsg*) (see Methods and Fig. S3J-L). Next, we utilized the transcriptomes of cells within these clusters to estimate a differentiation trajectory (Fig. S3M, see Methods for further details), in which higher DPT values correspond to more mature cells.

As expected, analysis of known self-renewing marker genes revealed downregulation of *vWF*, *Mpl*, *Fdg5*, *Cttnal1*, *Procr*, and upregulation of *Ctsg* and *Cbpa* as cells progressed from HSC to MPP (Fig. S3N).

We then estimated a DPT value along this trajectory for myHSC and balHSC from aged WT and Sema4AKO mice which were profiled in the Smart-Seq2 experiment described above.

Consistent with previously reported myHSC/balHSC hierarchy, the DPT values of WT aged myHSC were lower than WT balHSC, indicating that myHSC are more primitive than balHSC (Fig. S3O), (Carrelha et al., 2018; Morita *et al.*, 2010). Importantly, the comparison between aged WT myHSC and aged Sema4AKO myHSC revealed that the DPT values for aged Sema4AKO myHSC were higher, suggesting that they became more differentiated (p-value = 0.0002, Wilcoxon rank-sum test, Fig. 3M). Conversely, no significant difference was found between the DPT distributions of aged WT and aged Sema4AKO balHSC (Fig.3N). Thus, our DPT analysis demonstrates that the absence of Sema4A during aging leads to premature, myHSC-specific activation of the differentiation transcriptional program.

In sum, our immunophenotypic, functional and transcriptional analysis identified Sema4A as a critical regulator of myHSC self-renewal and differentiation. The profound loss of regenerative capacity in aged Sema4AKO myHSC, as observed in the transplant experiments, likely represents a cumulative effect of partially overlapping cellular defects, such as inflammatory injury, premature aging and accelerated differentiation.

Sema4A from the bone marrow niche restrains stress-induced myHSC proliferation and maintains self-renewal

Since *Sema4A* is expressed in both non-hematopoietic and hematopoietic cells, including HSC (Baccin *et al.*, 2020; Cabezas-Wallscheid *et al.*, 2017; Cabezas-Wallscheid *et al.*, 2014), we asked which cellular source of *Sema4A* was functionally indispensable for myHSC function. First, we investigated the role of HSC-derived *Sema4A* by employing conditional deletion with *Mx1-Cre*. We confirmed Cre-induced recombination of the “floxed” *Sema4A* allele in HSPC by PCR and Q-PCR analysis (Fig. S4A and S4B). Analysis of *Sema4A^{fl/fl}* *Mx1-Cre*(+) animals at the steady-state revealed no difference in peripheral blood counts, bone marrow cellularity, cell cycle and frequency of HSPC and mature cells, as compared to *Sema4A^{fl/fl}* *Mx1-Cre*(-) controls (Suppl. Table 1, Fig. S4C and S4D). In competitive transplantation assay, no difference in long-term reconstitution capacity of myHSC and balHSC from *Sema4A^{fl/fl}* *Mx1-Cre*(+) and *Sema4A^{fl/fl}* *Mx1-Cre*(-) mice was observed (Fig. 4A-B and Fig. S4E-G). These data indicate that hematopoietic-derived *Sema4A* is dispensable for myHSC and balHSC function.

In order to elucidate the role of bone marrow microenvironment-derived *Sema4A*, we non-competitively transplanted lethally irradiated WT and *Sema4AKO* recipients with a radioprotective dose of myHSC and balHSC from WT mice (Fig. 4C). Strikingly, we observed a ~50% post-transplant mortality in *Sema4AKO* recipients of myHSC (Fig. 4D, left panel). The surviving animals from this group displayed marked anemia and neutrophilia, which resembled blood count abnormalities in aged *Sema4AKO* mice (Fig. 4D, right panel and Fig. S4H). In contrast, no survival difference was observed in the recipients of balHSC, which showed only mild blood counts changes (Fig. 4E and Fig. S4I). This experiment revealed that *Sema4A* from the host hematopoietic niche is critical for myHSC self-renewal under stress but plays no significant role in balHSC regeneration.

Among the subsets which make up the bone marrow niche, *Sema4A* is expressed by endothelial and osteoprogenitor cells (Fig. S1A and Fig. S1B). In order to refine their

physiological relevance as cellular sources of *Sema4A* in the niche, we conditionally deleted *Sema4A* from each of the two cell types by crossing “floxed” *Sema4AKO* mice to either *VECad-CreERT2* or *Osx-Cre* animals. Steady-state analysis of *Sema4A*^{fl/fl} *VE-CadCre ERT2(+)* and *Sema4A*^{fl/fl} *Osx-Cre (+)* mice revealed no difference in peripheral blood counts, bone marrow cellularity, cell cycle and frequency of HSPC and mature cells, as compared to *Sema4A*^{fl/fl} *VE-CadCre ERT2(-)* (Sorensen et al., 2009) and *Sema4A*^{fl/wt} *Osx-Cre (+)* (Rodda and McMahon, 2006) controls, respectively (Fig. S4J-M and Suppl. Table 1). Transplantation of WT myHSC and balHSC into lethally irradiated donors of the above genotypes showed that both endothelial- and osteoprogenitor-specific deletion of *Sema4A* only partially recapitulated the effect of a complete *Sema4A* absence in the host. Specifically, we observed increased mortality in *Sema4A*^{fl/fl} *Osx-Cre (+)* recipients of myHSC, but the difference was not statistically significant (Fig. S4N-P). In *Sema4A*^{fl/fl} *VE-CadCre ERT2(+)* recipients of myHSC, we detected a slight reduction in hematocrit and no impact on survival (Fig. S4Q-S). Taken together, these studies suggest that a cumulative production by osteoprogenitors, endothelial cells and likely other cellular source(s) may be responsible for the full functional effect of microenvironment-derived *Sema4A* on myHSC.

Having demonstrated that a complete absence of *Sema4A* in the host is critical for myHSC engraftment (Fig. 4D), we asked how it may affect early homing, expansion and motility of transplanted myHSC in real time. To this end, we isolated myHSC and balHSC from WT mice and fluorescently labeled them with DiD. We then transferred equal numbers of these cells into lethally irradiated WT and *Sema4AKO* recipients and performed intravital time-lapse two-photon microscopy of the calvarial bone marrow (Christodoulou et al., 2020). We recorded 3D z-stacks and time-lapse movies 15-20 hours after the cell injection. Single cells and clusters (defined as two or more cells whose cell-to-cell edge are within 15 μm) were detected throughout the calvarial bone marrow in all mice (Fig. S4T). Notably, we observed a ~3 times

higher number of transplanted cells in *Sema4AKO* recipients of myHSC compared to WT controls (mean ~106 cells vs. 34 cells, [p-value = 0.0295]) whereas cell number in WT/*Sema4A* recipients of balHSC were not significantly different (mean ~68 cells vs. 41 cells, respectively [p-value = 0.2793]) (Fig. 4F and S4U). These results indicate that the absence of *Sema4A* in the host leads to excessive myHSC expansion but is inconsequential for balHSC. As further evidence for this, we found a similar 3-fold increase in the number of cell clusters in the *Sema4AKO* recipients of myHSC as compared to WT controls (mean ~21 vs. 7 clusters [p-value = 0.0219] whereas the trend in the balHSC recipients was much weaker (~15 vs. 8 clusters [p-value = 0.2591]) (Fig. S4V).

Next, we analyzed the effect of *Sema4A* on myHSC and balHSC localization by measuring the 3D distance to the endosteal surface, an established location of post-transplant HSC niche (Lo Celso et al., 2009). Importantly, we observed that in *Sema4AKO* recipients of myHSC, transplanted cells were found nearly 2x farther from the endosteum compared to WT controls (mean ~8.2 μm vs. 4.9 μm , respectively [p-value = 0.0024]) whereas this difference was smaller and not statistically significant in the *Sema4AKO*/WT balHSC recipients (mean ~5.9 μm vs. 4.0 μm , respectively [p-value = 0.0674]) (Fig. 4G). These results suggest that in the absence of host *Sema4A*, myHSC homed away from the niche, whereas localization of balHSC was only marginally altered.

Recent intravital time-lapse microscopy studies revealed that upon proliferative challenge, some HSC within the bone marrow niche become motile (Christodoulou *et al.*, 2020; Upadhaya et al., 2020), indicating that motility may reflect HSC activation state. In order to investigate if motility of transplanted myHSC and balHSC is altered in the absence of *Sema4A*, we performed time-lapse microscopy for 1.5 hrs. We found that balHSC displayed limited motility (defined as <5 μm movement of the cell centroid over the imaging period) regardless of the host genotype (data not shown). In contrast, a small fraction (~4.7% of total) of myHSC transplanted into

Sema4AKO mice exhibited highly motile behavior Sema4A (Fig. 4H, Fig.S4V-X, Suppl. Movie).

In sum, our intravital imaging data suggests that host absence of Sema4A leads to myHSC hyperactivation, excessive proliferation and mis-localization, which cumulatively may contribute to the loss of self-renewal and engraftment failure in Sema4AKO recipients of myHSC.

Intriguingly, post-transplant behavior of balHSC was relatively unaffected, indicating that the two HSC subsets may have fundamentally different requirements for engraftment, including specific dependence of myHSC on Sema4A.

DISCUSSION

Our study provides substantial experimental support for the concept that functionally diverse subsets of somatic stem cells are controlled by distinct non cell-autonomous signals. Prior studies have indicated that within the HSC pool, myHSC and balHSC display differential sensitivity to soluble factors, such as TGF-beta, RANTES, CXCL2 and histamine (Challen *et al.*, 2010; Chen *et al.*, 2017; Ergen *et al.*, 2012; Pinho *et al.*, 2018). However, the impact of these molecules on myHSC longevity and interaction with the bone marrow microenvironment has not been investigated in detail.

In the current study, we identify Sema4A as an indispensable and specific regulator of myHSC quiescence and self-renewal. Semaphorins and plexins are large protein families (Alto and Terman, 2017) whose role in regulation of adult stem cell quiescence and self-renewal is not known. We demonstrate that the absence of Sema4A leads to myHSC over-proliferation and hyperactivation following acute inflammatory insult, which correlates with a dramatic loss of regenerative function with age, likely due to the loss of protection from detrimental effects of inflammatory signaling over the animal's lifetime (Kaschutnig *et al.*, 2015). Notably, WT myHSC are preferentially activated by inflammation (Mann *et al.*, 2018; Matatall *et al.*, 2014; Mitroulis *et*

et al., 2018) and become vulnerable to damage, underscoring a physiological need for a dedicated protective signal, such as Sema4A.

Excessive myeloid expansion, as observed in the aged Sema4AKO model, is the cardinal feature of human hematopoietic aging (Pang *et al.*, 2011) and clonal hematopoiesis of indeterminate significance (CHIP) - a common condition which carries a significant risk of progression to myeloid malignancy over time but lacks effective therapeutic intervention (Jaiswal and Ebert, 2019). Our findings raise a possibility that pharmacological augmentation of Sema4A/PlxnD1 signaling may serve as a potential strategy to constrain proliferation of myHSC at the top of expanding myeloid-biased clones, thereby preventing aging-associated HSC dysfunction and reducing the risk of malignant transformation.

Our results underscore the importance of niche-derived signals in life-long maintenance of tissue stem cell hierarchy, which is topped by myHSC in the hematopoietic system. Given that stem cell hierarchies underlie functional organization of other tissues (Altshuler *et al.*, 2021; Farrelly *et al.*, 2021; Hsu *et al.*, 2011; Rompolas *et al.*, 2013; Sachewsky *et al.*, 2019; Scaramozza *et al.*, 2019), the data presented here provide justification for broader efforts to identify subset-specific stem cell regulators, which may lead to development of more precise and effective pro-regenerative therapies.

LIMITATIONS OF THE STUDY

Recent studies revealed that CD150-expressing phenotypic HSC contain a heterogeneous mixture of myeloid-restricted progenitors which vary in their capacity for long-term reconstitution and degree of commitment to myeloid, erythroid and platelet lineage (Yamamoto *et al.*, 2018). We recognize that our experiments are unable to resolve the precise identity of a myeloid-restricted subset(s) which is regulated by Sema4A beyond the CD150^{high} HSC fraction. Future

studies, including single cell transplantation experiments, will be required to address this question.

Although our data demonstrates that Sema4A suppresses myHSC proliferation during stress, the downstream mediators of this effect are not known. Therefore, the molecular consequences of Sema4A binding to PlxnD1 (and potentially other Sema4A receptors whose functional relevance has not been ruled out by the current study) will need to be further investigated.

ACKNOWLEDGMENTS

Work in the Silberstein Laboratory is supported by the NIH/NHLBI (R01 HL148189), Translational Research Program grant through Leukemia and Lymphoma Society, Washington State CARE Fund and New Development Fund from Fred Hutchinson Cancer Research Center. The work in the Göttgens laboratory was funded in part by the Wellcome Trust [203151/Z/16/Z] and the UKRI Medical Research Council [MC_PC_17230]. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. The work in the Maes laboratory is supported by grants from the Research Foundation Flanders (FWO) and KU Leuven (C1). The schematics were created with BioRender.com.

We would like to thank Elena Nefyodova (KU Leuven) for expert technical help, Michael Li, Zoe Derauf, Ben Janoschek and Kora Krumm for mouse colony support, and the staff of Flow Cytometry, Genomics and Comparative Medicine cores facilities at Fred Hutchinson Cancer Research Center. We are also grateful to Peter Klein, University of Pennsylvania, and Adam Wilkinson, University of Oxford, for helpful feedback and advice.

AUTHOR CONTRIBUTIONS

DT and SZ designed and performed experiments, analyzed and interpreted data, and wrote the manuscript. EM performed computational analyses of sequencing data and contributed to data interpretation. EIC performed experiments, computational analyses of sequencing data and contributed to experimental design and data interpretation. AS data supervised all the computational analyses of sequencing data and contributed to data interpretation. AP supported mouse breeding and performed experiments. NT, CB and DG performed intravital imaging experiments under the supervision of JAS. SR, HPK designed and performed human HSC experiments. NKW and SJK performed single cell RNA-Seq experiments under the supervision of BG. CN, MM, CM and PK contributed data. SR and NC performed experiments with aged mice. TW and AK contributed reagents. EMP and DTS contributed to experimental design and data discussion. L.S. conceived and supervised the project, performed experiments, analyzed data and wrote the manuscript.

DECLARATION OF INTERESTS

SR: Ensoma Inc.: Consultancy; 47 Inc.: Consultancy. HPK: Ensoma Inc.: Consultancy, Current holder of individual stocks in a privately-held company; Homology Medicines: Consultancy; VOR Biopharma: Consultancy. DTS: Fate Therapeutics: Current holder of individual stocks in a privately-held company; Editas Medicines: Current holder of individual stocks in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Clear Creek Bio: Current holder of individual stocks in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Dainippon Sumitomo Pharma: Other: sponsored research; FOG Pharma: Consultancy; Agios Pharmaceuticals: Current holder of individual stocks in a privately-held company, Membership on an entity's Board of Directors or advisory

committees; Garuda Therapeutics: Current holder of individual stocks in a privately-held company, Membership on an entity's Board of Directors or advisory committees; VCanBio: Consultancy; Inzen Therapeutics: Membership on an entity's Board of Directors or advisory committees; LifeVaultBio: Current holder of individual stocks in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Magenta Therapeutics: Current holder of individual stocks in a privately-held company, Membership on an entity's Board of Directors or advisory committees. Other authors have nothing to disclose.

REFERENCES

- Alto, L.T., and Terman, J.R. (2017). Semaphorins and their Signaling Mechanisms. *Methods Mol Biol* 1493, 1-25. 10.1007/978-1-4939-6448-2_1.
- Altshuler, A., Amitai-Lange, A., Tarazi, N., Dey, S., Strinkovsky, L., Hadad-Porat, S., Bhattacharya, S., Nasser, W., Imeri, J., Ben-David, G., et al. (2021). Discrete limbal epithelial stem cell populations mediate corneal homeostasis and wound healing. *Cell Stem Cell* 28, 1248-1261 e1248. 10.1016/j.stem.2021.04.003.
- Baccin, C., Al-Sabah, J., Velten, L., Helbling, P.M., Grunschlager, F., Hernandez-Malmierca, P., Nombela-Arrieta, C., Steinmetz, L.M., Trumpp, A., and Haas, S. (2020). Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization. *Nat Cell Biol* 22, 38-48. 10.1038/s41556-019-0439-6.
- Becker-Herman, S., Rozenberg, M., Hillel-Karniel, C., Gil-Yarom, N., Kramer, M.P., Barak, A., Sever, L., David, K., Radomir, L., Lewinsky, H., et al. (2021). CD74 is a regulator of hematopoietic stem cell maintenance. *PLoS Biol* 19, e3001121. 10.1371/journal.pbio.3001121.
- Beerman, I., Bhattacharya, D., Zandi, S., Sigvardsson, M., Weissman, I.L., Bryder, D., and Rossi, D.J. (2010). Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. *Proc Natl Acad Sci U S A* 107, 5465-5470. 10.1073/pnas.1000834107.
- Bernitz, J.M., Kim, H.S., MacArthur, B., Sieburg, H., and Moore, K. (2016). Hematopoietic Stem Cells Count and Remember Self-Renewal Divisions. *Cell* 167, 1296-1309 e1210. 10.1016/j.cell.2016.10.022.
- Cabezas-Wallscheid, N., Buettner, F., Sommerkamp, P., Klimmeck, D., Ladel, L., Thalheimer, F.B., Pastor-Flores, D., Roma, L.P., Renders, S., Zeisberger, P., et al. (2017). Vitamin A-Retinoic Acid Signaling Regulates Hematopoietic Stem Cell Dormancy. *Cell* 169, 807-823 e819. 10.1016/j.cell.2017.04.018.
- Cabezas-Wallscheid, N., Klimmeck, D., Hansson, J., Lipka, D.B., Reyes, A., Wang, Q., Weichenhan, D., Lier, A., von Paleske, L., Renders, S., et al. (2014). Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis. *Cell Stem Cell* 15, 507-522. 10.1016/j.stem.2014.07.005.
- Calvanese, V., Nguyen, A.T., Bolan, T.J., Vavilina, A., Su, T., Lee, L.K., Wang, Y., Lay, F.D., Magnusson, M., Crooks, G.M., et al. (2019). MLLT3 governs human haematopoietic stem-cell self-renewal and engraftment. *Nature* 576, 281-286. 10.1038/s41586-019-1790-2.
- Carrelha, J., Meng, Y., Kettyle, L.M., Luis, T.C., Norfo, R., Alcolea, V., Boukarabila, H., Grasso, F., Gambardella, A., Grover, A., et al. (2018). Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells. *Nature* 554, 106-111. 10.1038/nature25455.
- Challen, G.A., Boles, N.C., Chambers, S.M., and Goodell, M.A. (2010). Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. *Cell Stem Cell* 6, 265-278. 10.1016/j.stem.2010.02.002.
- Chen, X., Deng, H., Churchill, M.J., Luchsinger, L.L., Du, X., Chu, T.H., Friedman, R.A., Middelhoff, M., Ding, H., Taylor, Y.H., et al. (2017). Bone Marrow Myeloid Cells Regulate Myeloid-Biased Hematopoietic Stem Cells via a Histamine-Dependent Feedback Loop. *Cell Stem Cell* 21, 747-760 e747. 10.1016/j.stem.2017.11.003.

- Christodoulou, C., Spencer, J.A., Yeh, S.A., Turcotte, R., Kokkaliaris, K.D., Panero, R., Ramos, A., Guo, G., Seyedhassantehrani, N., Esipova, T.V., et al. (2020). Live-animal imaging of native haematopoietic stem and progenitor cells. *Nature* 578, 278-283. 10.1038/s41586-020-1971-z.
- Ergen, A.V., Boles, N.C., and Goodell, M.A. (2012). Rantes/Ccl5 influences hematopoietic stem cell subtypes and causes myeloid skewing. *Blood* 119, 2500-2509. 10.1182/blood-2011-11-391730.
- Esplin, B.L., Shimazu, T., Welner, R.S., Garrett, K.P., Nie, L., Zhang, Q., Humphrey, M.B., Yang, Q., Borghesi, L.A., and Kincade, P.W. (2011). Chronic exposure to a TLR ligand injures hematopoietic stem cells. *J Immunol* 186, 5367-5375. 10.4049/jimmunol.1003438.
- Fang, S., Chen, S., Nurmi, H., Leppanen, V.M., Jeltsch, M., Scadden, D., Silberstein, L., Mikkola, H., and Alitalo, K. (2020). VEGF-C protects the integrity of the bone marrow perivascular niche in mice. *Blood* 136, 1871-1883. 10.1182/blood.2020005699.
- Fard, D., and Tamagnone, L. (2021). Semaphorins in health and disease. *Cytokine Growth Factor Rev* 57, 55-63. 10.1016/j.cytogfr.2020.05.006.
- Farrelly, O., Suzuki-Horiuchi, Y., Brewster, M., Kuri, P., Huang, S., Rice, G., Bae, H., Xu, J., Dentchev, T., Lee, V., and Rompolas, P. (2021). Two-photon live imaging of single corneal stem cells reveals compartmentalized organization of the limbal niche. *Cell Stem Cell* 28, 1233-1247 e1234. 10.1016/j.stem.2021.02.022.
- Goncalves, K.A., Silberstein, L., Li, S., Severe, N., Hu, M.G., Yang, H., Scadden, D.T., and Hu, G.F. (2016). Angiogenin Promotes Hematopoietic Regeneration by Dichotomously Regulating Quiescence of Stem and Progenitor Cells. *Cell* 166, 894-906. 10.1016/j.cell.2016.06.042.
- Gong, S., Zheng, C., Doughty, M.L., Losos, K., Didkovsky, N., Schambra, U.B., Nowak, N.J., Joyner, A., Leblanc, G., Hatten, M.E., and Heintz, N. (2003). A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. *Nature* 425, 917-925. 10.1038/nature02033.
- Grover, A., Sanjuan-Pla, A., Thongjuea, S., Carrelha, J., Giustacchini, A., Gambardella, A., Macaulay, I., Mancini, E., Luis, T.C., Mead, A., et al. (2016). Single-cell RNA sequencing reveals molecular and functional platelet bias of aged haematopoietic stem cells. *Nat Commun* 7, 11075. 10.1038/ncomms11075.
- Haghverdi, L., Buttner, M., Wolf, F.A., Buettner, F., and Theis, F.J. (2016). Diffusion pseudotime robustly reconstructs lineage branching. *Nat Methods* 13, 845-848. 10.1038/nmeth.3971.
- Hirche, C., Frenz, T., Haas, S.F., Doring, M., Borst, K., Tegtmeyer, P.K., Brizic, I., Jordan, S., Keyser, K., Chhatbar, C., et al. (2017). Systemic Virus Infections Differentially Modulate Cell Cycle State and Functionality of Long-Term Hematopoietic Stem Cells In Vivo. *Cell Rep* 19, 2345-2356. 10.1016/j.celrep.2017.05.063.
- Hsu, Y.C., Pasolli, H.A., and Fuchs, E. (2011). Dynamics between stem cells, niche, and progeny in the hair follicle. *Cell* 144, 92-105. 10.1016/j.cell.2010.11.049.
- Jaiswal, S., and Ebert, B.L. (2019). Clonal hematopoiesis in human aging and disease. *Science* 366. 10.1126/science.aan4673.
- Kaschutnig, P., Bogeska, R., Walter, D., Lier, A., Huntscha, S., and Milsom, M.D. (2015). The Fanconi anemia pathway is required for efficient repair of stress-induced DNA damage in haematopoietic stem cells. *Cell Cycle* 14, 2734-2742. 10.1080/15384101.2015.1068474.
- Kent, D.G., Copley, M.R., Benz, C., Wohrer, S., Dykstra, B.J., Ma, E., Cheyne, J., Zhao, Y., Bowie, M.B., Zhao, Y., et al. (2009). Prospective isolation and molecular characterization of

- hematopoietic stem cells with durable self-renewal potential. *Blood* 113, 6342-6350. 10.1182/blood-2008-12-192054.
- Kent, D.G., Dykstra, B.J., Cheyne, J., Ma, E., and Eaves, C.J. (2008). Steel factor coordinately regulates the molecular signature and biologic function of hematopoietic stem cells. *Blood* 112, 560-567. 10.1182/blood-2007-10-117820.
- Kolodkin, A.L., Matthes, D.J., and Goodman, C.S. (1993). The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. *Cell* 75, 1389-1399. 10.1016/0092-8674(93)90625-z.
- Kovtonyuk, L.V., Fritsch, K., Feng, X., Manz, M.G., and Takizawa, H. (2016). Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment. *Front Immunol* 7, 502. 10.3389/fimmu.2016.00502.
- Kuhn, R., Schwenk, F., Aguet, M., and Rajewsky, K. (1995). Inducible gene targeting in mice. *Science* 269, 1427-1429. 10.1126/science.7660125.
- Kumanogoh, A., Shikina, T., Suzuki, K., Uematsu, S., Yukawa, K., Kashiwamura, S., Tsutsui, H., Yamamoto, M., Takamatsu, H., Ko-Mitamura, E.P., et al. (2005). Nonredundant roles of Sema4A in the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice. *Immunity* 22, 305-316. 10.1016/j.immuni.2005.01.014.
- Laurenti, E., Frelin, C., Xie, S., Ferrari, R., Dunant, C.F., Zandi, S., Neumann, A., Plumb, I., Doulatov, S., Chen, J., et al. (2015). CDK6 levels regulate quiescence exit in human hematopoietic stem cells. *Cell Stem Cell* 16, 302-313. 10.1016/j.stem.2015.01.017.
- Lo Celso, C., Fleming, H.E., Wu, J.W., Zhao, C.X., Miake-Lye, S., Fujisaki, J., Cote, D., Rowe, D.W., Lin, C.P., and Scadden, D.T. (2009). Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. *Nature* 457, 92-96. 10.1038/nature07434.
- Mann, M., Mehta, A., de Boer, C.G., Kowalczyk, M.S., Lee, K., Haldeman, P., Rogel, N., Knecht, A.R., Farouq, D., Regev, A., and Baltimore, D. (2018). Heterogeneous Responses of Hematopoietic Stem Cells to Inflammatory Stimuli Are Altered with Age. *Cell Rep* 25, 2992-3005 e2995. 10.1016/j.celrep.2018.11.056.
- Matatall, K.A., Shen, C.C., Challen, G.A., and King, K.Y. (2014). Type II interferon promotes differentiation of myeloid-biased hematopoietic stem cells. *Stem Cells* 32, 3023-3030. 10.1002/stem.1799.
- Mitroulis, I., Ruppova, K., Wang, B., Chen, L.S., Grzybek, M., Grinenko, T., Eugster, A., Troullinaki, M., Palladini, A., Kourtzelis, I., et al. (2018). Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity. *Cell* 172, 147-161 e112. 10.1016/j.cell.2017.11.034.
- Montecino-Rodriguez, E., Kong, Y., Casero, D., Rouault, A., Dorshkind, K., and Pioli, P.D. (2019). Lymphoid-Biased Hematopoietic Stem Cells Are Maintained with Age and Efficiently Generate Lymphoid Progeny. *Stem Cell Reports* 12, 584-596. 10.1016/j.stemcr.2019.01.016.
- Morcos, M.N.F., Schoedel, K.B., Hoppe, A., Behrendt, R., Basak, O., Clevers, H.C., Roers, A., and Gerbaulet, A. (2017). SCA-1 Expression Level Identifies Quiescent Hematopoietic Stem and Progenitor Cells. *Stem Cell Reports* 8, 1472-1478. 10.1016/j.stemcr.2017.04.012.
- Morita, Y., Ema, H., and Nakauchi, H. (2010). Heterogeneity and hierarchy within the most primitive hematopoietic stem cell compartment. *J Exp Med* 207, 1173-1182. 10.1084/jem.20091318.

- Nestorowa, S., Hamey, F.K., Pijuan Sala, B., Diamanti, E., Shepherd, M., Laurenti, E., Wilson, N.K., Kent, D.G., and Gottgens, B. (2016). A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation. *Blood* 128, e20-31. 10.1182/blood-2016-05-716480.
- Pang, W.W., Price, E.A., Sahoo, D., Beerman, I., Maloney, W.J., Rossi, D.J., Schrier, S.L., and Weissman, I.L. (2011). Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. *Proc Natl Acad Sci U S A* 108, 20012-20017. 10.1073/pnas.1116110108.
- Picelli, S., Faridani, O.R., Bjorklund, A.K., Winberg, G., Sagasser, S., and Sandberg, R. (2014). Full-length RNA-seq from single cells using Smart-seq2. *Nat Protoc* 9, 171-181. 10.1038/nprot.2014.006.
- Pinho, S., Marchand, T., Yang, E., Wei, Q., Nerlov, C., and Frenette, P.S. (2018). Lineage-Biased Hematopoietic Stem Cells Are Regulated by Distinct Niches. *Dev Cell* 44, 634-641 e634. 10.1016/j.devcel.2018.01.016.
- Rodda, S.J., and McMahon, A.P. (2006). Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. *Development* 133, 3231-3244. 10.1242/dev.02480.
- Rodriguez-Fraticelli, A.E., Weinreb, C., Wang, S.W., Migueles, R.P., Jankovic, M., Usart, M., Klein, A.M., Lowell, S., and Camargo, F.D. (2020). Single-cell lineage tracing unveils a role for TCF15 in haematopoiesis. *Nature* 583, 585-589. 10.1038/s41586-020-2503-6.
- Rompolas, P., Mesa, K.R., and Greco, V. (2013). Spatial organization within a niche as a determinant of stem-cell fate. *Nature* 502, 513-518. 10.1038/nature12602.
- Sachewsky, N., Xu, W., Fuehrmann, T., van der Kooy, D., and Morshead, C.M. (2019). Lineage tracing reveals the hierarchical relationship between neural stem cell populations in the mouse forebrain. *Sci Rep* 9, 17730. 10.1038/s41598-019-54143-9.
- Sanjuan-Pla, A., Macaulay, I.C., Jensen, C.T., Woll, P.S., Luis, T.C., Mead, A., Moore, S., Carella, C., Matsuoka, S., Bouriez Jones, T., et al. (2013). Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. *Nature* 502, 232-236. 10.1038/nature12495.
- Scaramozza, A., Park, D., Kollu, S., Beerman, I., Sun, X., Rossi, D.J., Lin, C.P., Scadden, D.T., Crist, C., and Brack, A.S. (2019). Lineage Tracing Reveals a Subset of Reserve Muscle Stem Cells Capable of Clonal Expansion under Stress. *Cell Stem Cell* 24, 944-957 e945. 10.1016/j.stem.2019.03.020.
- Scialdone, A., Natarajan, K.N., Saraiva, L.R., Proserpio, V., Teichmann, S.A., Stegle, O., Marioni, J.C., and Buettner, F. (2015). Computational assignment of cell-cycle stage from single-cell transcriptome data. *Methods* 85, 54-61. 10.1016/j.ymeth.2015.06.021.
- Serini, G., Valdembrì, D., Zanivan, S., Morterra, G., Burkhardt, C., Caccavari, F., Zammataro, L., Primo, L., Tamagnone, L., Logan, M., et al. (2003). Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. *Nature* 424, 391-397. 10.1038/nature01784.
- Silberstein, L., Goncalves, K.A., Kharchenko, P.V., Turcotte, R., Kfoury, Y., Mercier, F., Baryawno, N., Severe, N., Bachand, J., Spencer, J.A., et al. (2016). Proximity-Based Differential Single-Cell Analysis of the Niche to Identify Stem/Progenitor Cell Regulators. *Cell Stem Cell* 19, 530-543. 10.1016/j.stem.2016.07.004.
- Sorensen, I., Adams, R.H., and Gossler, A. (2009). DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries. *Blood* 113, 5680-5688. 10.1182/blood-2008-08-174508.

- Takizawa, H., Regoes, R.R., Boddupalli, C.S., Bonhoeffer, S., and Manz, M.G. (2011). Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. *J Exp Med* 208, 273-284. 10.1084/jem.20101643.
- Toyofuku, T., Yabuki, M., Kamei, J., Kamei, M., Makino, N., Kumanogoh, A., and Hori, M. (2007). Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1. *EMBO J* 26, 1373-1384. 10.1038/sj.emboj.7601589.
- Upadhaya, S., Krichevsky, O., Akhmetzyanova, I., Sawai, C.M., Fooksman, D.R., and Reizis, B. (2020). Intravital Imaging Reveals Motility of Adult Hematopoietic Stem Cells in the Bone Marrow Niche. *Cell Stem Cell* 27, 336-345 e334. 10.1016/j.stem.2020.06.003.
- Valletta, S., Thomas, A., Meng, Y., Ren, X., Drissen, R., Sengul, H., Di Genua, C., and Nerlov, C. (2020). Micro-environmental sensing by bone marrow stroma identifies IL-6 and TGFbeta1 as regulators of hematopoietic ageing. *Nat Commun* 11, 4075. 10.1038/s41467-020-17942-7.
- Walter, D., Lier, A., Geiselhart, A., Thalheimer, F.B., Huntscha, S., Sobotta, M.C., Moehrl, B., Brocks, D., Bayindir, I., Kaschutnig, P., et al. (2015). Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. *Nature* 520, 549-552. 10.1038/nature14131.
- Yamamoto, R., Wilkinson, A.C., Ooehara, J., Lan, X., Lai, C.Y., Nakauchi, Y., Pritchard, J.K., and Nakauchi, H. (2018). Large-Scale Clonal Analysis Resolves Aging of the Mouse Hematopoietic Stem Cell Compartment. *Cell Stem Cell* 22, 600-607 e604. 10.1016/j.stem.2018.03.013.
- Yu, W., Goncalves, K.A., Li, S., Kishikawa, H., Sun, G., Yang, H., Vanli, N., Wu, Y., Jiang, Y., Hu, M.G., et al. (2017). Plexin-B2 Mediates Physiologic and Pathologic Functions of Angiogenin. *Cell* 171, 849-864 e825. 10.1016/j.cell.2017.10.005.
- Zhang, Y., Singh, M.K., Degenhardt, K.R., Lu, M.M., Bennett, J., Yoshida, Y., and Epstein, J.A. (2009). Tie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defects. *Dev Biol* 325, 82-93. 10.1016/j.ydbio.2008.09.031.

A

B

C

D

E

F

G

Figure 1

Figure 2

Figure 3

Figure 4

MAIN FIGURE LEGENDS

Figure 1. Sema4A regulates quiescence of mouse and human hematopoietic stem/progenitor cells.

(A) Expression of Sema4A in single proximal and distal osteolineage cells. The joint posteriors (black lines) describe the overall estimation of likely expression levels within the proximal (top) and distal (bottom) OLCs and are used to estimate the posterior of the expression fold difference (middle plot). The shaded area under the fold-difference posterior shows 95% confidence region. FPM, fragments per million.

(B) The number of mouse LKS cells 24 hours after addition of mouse Sema4A-Fc/IgG1 control protein (n=5 technical replicates per condition).

(C) CFSE dilution analysis of *ex vivo* proliferation kinetics of human CD34⁺ cells 24 hours after addition of human Sema4A-Fc/IgG1 protein (n=5 technical replicates per condition, Donor 1). Estimated number of divided cells and representative CFSE fluorescence histograms are shown.

(D) Immunophenotypic analysis of the bone marrow from young WT/Sema4AKO mice (n=3-6 per genotype).

(E) HSC cell cycle analysis using DAPI/Ki-67 staining in young WT/Sema4AKO mice (n=6 per genotype).

(F) Gene set enrichment analysis (GSEA) of single cell RNA-Seq data for the HSC cluster (as defined in Figure S1K) from young WT/Sema4AKO mice. FDR<0.01, top five enriched pathways are shown.

(G) GSEA plots for the pathways as shown in (F).

Data are presented as mean $\pm$ SD *p < 0.05; **p < 0.01; ***p < 0.001 by unpaired T-test.

Figure 2. Sema4A/PlxnD1 signaling constrains the response of myeloid-biased HSC to proliferative stress.

(A) Experimental schema for the acute inflammatory stress model.

(B) Cell cycle analysis of myHSC 24 hours after injection with Poly(I:C) (n=5 mice per genotype).

(C) Cell cycle analysis of balHSC 24 hours after injection with Poly(I:C) (n=5 mice per genotype).

(D) WT vs Sema4AKO GSEA of myHSC from Poly(I:C) injected mice, FDR<0.01.

(E) GSEA plots and top differentially expressed genes for the pathways that were enriched in Sema4AKO myHSC, as shown in (D).

(F) Experimental schema for the transplant studies as shown in (G) and (H).

- (G) Donor chimerism in the recipients of myHSC from young WT/Sema4AKO mice (n=5 mice per donor genotype).
- (H) Donor chimerism in the recipients of balHSC from young WT/Sema4AKO mice (n=4-5 mice per donor genotype).
- (I) Published HSC gene expression data (Cabezas-Wallscheid et al., 2014) showing expression of known Sema4A receptors.
- (J) Representative histograms (left panel) and quantification of mean fluorescence intensity of GFP expression (right panel) in myHSC (pink) and balHSC (blue) from PlxnD1-GFP reporter mice (n=3 mice).
- (K) Donor chimerism in the recipients of myHSC from PlxnD1^{fl/fl} Mx1-Cre(+) and PlxnD1^{fl/fl} Mx1-Cre (-) mice (n=5 recipient mice per genotype).
- (L) Donor chimerism in the recipients of balHSC from PlxnD1^{fl/fl} Mx1-Cre(+) and PlxnD1^{fl/fl} Mx1-Cre (-) mice (n=5 recipient mice per genotype).

Data are presented as mean $\pm$ SD *p < 0.05; **p < 0.01; ***p < 0.001 by unpaired T-test.

Figure 3. Sema4A prevents excessive myHSC expansion and functional loss with age.

- (A) Serial peripheral blood counts of WT and Sema4AKO mice during aging (n=4-9 mice per genotype, age range 8-74 weeks).
- (B) Immunophenotypic analysis of the bone marrow from aged (74-weeks old) WT/Sema4AKO mice (n=4-5 mice per genotype).
- (C) Frequency of myHSC and balHSC in aged (74-weeks old) WT/Sema4AKO mice (representative flow cytometry plots shown on the right) (n=4-5 mice per genotype).
- (D) Experimental schema for competitive myHSC/balHSC transplantation experiments shown in (E) and (F).
- (E) Donor chimerism in the recipients of myHSC from aged WT/Sema4AKO mice (n=3-5 per donor genotype).
- (F) Donor chimerism in the recipients of balHSC from aged WT/Sema4AKO mice (n=4-5 per donor genotype).
- (G) UMAP representation of 162 myHSC from aged WT and Sema4AKO mice (n=2 mice per genotype).
- (H) UMAP representation of 165 balHSC cells from WT and Sema4AKO mice (n=2 mice per genotype).
- (I) Distribution of pairwise Spearman's correlation distances between aged WT and Sema4AKO myHSC (left) and balHSC (right). The two distributions are statistically significantly different according to a Wilcoxon rank-sum test (p-value = 3.1e-85).

(J) GSEA of myHSC from aged WT/Sema4AKO mice, FDR<0.01.

(K) GSEA plots and top differentially expressed genes for pathways enriched in Sema4AKO myHSC.

(L) Percentage of myHSC and balHSC cells from aged WT/Sema4AKO in the G2M phase of the cell cycle as estimated from their transcriptome using *Cyclone*.

(M, N) Distributions of diffusion pseudotime values of myHSC (panel M) and balHSC (panel N) from aged WT/Sema4AKO. The P-values shown at the bottom were computed with a Wilcoxon-rank sum test.

Data are presented as mean $\pm$ SD *p < 0.05; **p < 0.01; ***p < 0.001 by unpaired T-test.

Figure 4. Sema4A from the bone marrow niche restrains stress-induced myHSC proliferation and maintains self-renewal.

(A) Donor chimerism in the recipients of myHSC from Sema4A^{fl/fl} Cre(+) and Sema4A^{fl/fl} Cre(-) mice (n=4-5 mice per donor genotype).

(B) Donor chimerism in the recipients of balHSC from Sema4A^{fl/fl} Cre(+) and Sema4A^{fl/fl} Cre(-) mice (n=4-5 mice per donor genotype).

(C) Experimental schema for non-competitive transplant experiments shown in (D) and (E).

(D) Survival curve (left panel) and hematocrit/neutrophil count (right panel) in WT/Sema4AKO recipients of myHSC (data are the summary of 6 independent experiments involving a total of 9-11 recipients per genotype).

(E) Survival curve and peripheral blood counts in WT/Sema4AKO recipients of balHSC (data are the summary of 6 independent experiments involving a total of 9-11 recipients per genotype).

(F) Average number of cells per mouse ~15-20 hours after transplantation of WT myHSC or balHSC into WT/Sema4AKO recipients, as assessed by two-photon intravital imaging of the calvarial bone marrow (Data are the summary of 6 independent experiments involving a total of 4-6 recipients per genotype).

(G) Quantification of 3D distances between individual transplanted cells and the nearest endosteal surface (n = 171, 628, 161, and 266 total cells for WT myHSC, Sema4AKO myHSC, WT balHSC, and Sema4AKO balHSC, respectively; Data are the summary of 6 independent experiments involving a total of 4-6 recipients per group).

(H) Representative time-lapse two-photon intravital image of single motile WT myHSC in the calvaria of Sema4AKO recipient. Each cell and white arrow correspond to a different timepoint at increments of 10 mins. The myHSC (DiD, red), bone (SHG, green), and autofluorescence (blue) are shown. Scale Bar ~ 25 μ m.

Data are presented as mean $\pm$ SD *p < 0.05; **p < 0.01; ***p < 0.001 by unpaired T-test.